Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q2 FY20 results · Jul–Sep 2019
Torrent Pharmaceuticals reported revenue from operations of ₹2,005.00 crore (up 5.9% from Q2 FY19) and net profit of ₹244.00 crore (up 36.3% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,005.00 | 1,894.00 | +5.9% | 2,022.00 | −0.8% |
| Other income | 34.00 | 10.00 | +240.0% | 20.00 | +70.0% |
| Total income | 2,039.00 | 1,904.00 | +7.1% | 2,042.00 | −0.1% |
| Profit before tax | 296.00 | 205.00 | +44.4% | 279.00 | +6.1% |
| Net profit for the period | 244.00 | 179.00 | +36.3% | 216.00 | +13.0% |
| EPS, basic (₹) | 14.48 | 10.57 | +37.0% | 12.74 | +13.7% |
| Net margin (%) | 12.2 | 9.5 | 10.7 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,603.00 | 1,472.00 | +8.9% | 1,603.00 | +0.0% |
| Other income | 123.00 | 108.00 | +13.9% | 31.00 | +296.8% |
| Total income | 1,726.00 | 1,580.00 | +9.2% | 1,634.00 | +5.6% |
| Profit before tax | 393.00 | 300.00 | +31.0% | 277.00 | +41.9% |
| Net profit for the period | 328.00 | 277.00 | +18.4% | 223.00 | +47.1% |
| EPS, basic (₹) | 19.40 | 16.38 | +18.4% | 13.18 | +47.2% |
| Net margin (%) | 20.5 | 18.8 | 13.9 |
Consolidated
- Filed with BSE
- 24 Oct 2019, 11:17 IST
- Board meeting
- 23 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Oct 2019, 11:17 IST
- Board meeting
- 23 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Audited
- Source
- XBRL filing on BSE